Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01232595 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT01232595 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 109 participants.
The verdict
NCT01232595, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.
Interventions
- DRUG LFF571
- DRUG Vancomycin (POC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01232595
The ClinicalTrials.gov registry entry for NCT01232595 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LFF571 is the first listed.
NCT01232595 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01232595 about?
NCT01232595 is a clinical study titled "Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections". This study will assess the safety and efficacy of multiple daily dosing of oral LFF571 in patients who have moderate Clostridium difficile infections.
What is the current status of trial NCT01232595?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2010-10. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01232595?
The interventions under investigation include: LFF571 (DRUG), Vancomycin (POC) (DRUG).
Who is sponsoring clinical trial NCT01232595?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.